RESUMO
Aquagenic pruritus (AP) has a significant influence on quality of life (QoL) in patients with polycythaemia vera. This study analysed the impact of AP on patient well-being in 102 patients with polycythaemia vera. Intensity of pruritus was evaluated using a visual analogue scale (VAS), verbal rating scale (VRS) and a 4-item Itch Questionnaire. Psychosocial aspects of AP were assessed with the Hospital Anxiety and Depression Scale (HADS), EQ-5D and itch-specific QoL questionnaire (ItchyQoL). AP of mean duration 6.6 ± 8.6 years and intensity 4.8 ± 1.9 points (VAS) was present in 42/102 individuals. The prevalence of depression and anxiety among patients with AP was 23.8% and 9.5%, respectively. Depression was more frequent in the AP group (vs. non-AP). Moreover, patients with AP had higher HADS-anxiety scoring than those without pruritus (p = 0.005). A negative correlation was found between duration of AP and EQ-5D-VAS. The ItchyQol score of 37.3 ± 12.3 points was influenced by the extent (p =0.01) and duration of episodes of AP (p = 0.02). In conclusion, AP places an additional burden on patients with polycy-thaemia vera, negatively influencing their QoL.
Assuntos
Efeitos Psicossociais da Doença , Prurido/epidemiologia , Qualidade de Vida , Água/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Ansiedade/diagnóstico , Ansiedade/epidemiologia , Ansiedade/psicologia , Depressão/diagnóstico , Depressão/epidemiologia , Depressão/psicologia , Feminino , Humanos , Masculino , Saúde Mental , Pessoa de Meia-Idade , Polônia/epidemiologia , Policitemia Vera/diagnóstico , Policitemia Vera/epidemiologia , Policitemia Vera/psicologia , Policitemia Vera/terapia , Prevalência , Prurido/diagnóstico , Prurido/psicologia , Prurido/terapia , Fatores de Risco , Inquéritos e QuestionáriosRESUMO
BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODS: A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTS: Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. CONCLUSIONS: The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management. Cancer 2016;122:1888-96. © 2016 American Cancer Society.
Assuntos
Transtornos Mieloproliferativos/fisiopatologia , Transtornos Mieloproliferativos/psicologia , Disfunções Sexuais Fisiológicas/etiologia , Disfunções Sexuais Psicogênicas/etiologia , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Policitemia Vera/fisiopatologia , Policitemia Vera/psicologia , Mielofibrose Primária/fisiopatologia , Mielofibrose Primária/psicologia , Qualidade de Vida , Comportamento Sexual , Sexualidade , Inquéritos e Questionários , Trombocitemia Essencial/fisiopatologia , Trombocitemia Essencial/psicologiaRESUMO
BACKGROUND: BCR-ABL-negative myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases, including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). Psychological manifestations among these diseases have not been adequately described. METHODS: Cross-sectional surveys measuring distress, anxiety, and depression were collected from patients with BCR-ABL-negative MPNs from May 2015 to October 2015. Participants provided demographic information and completed the Distress Thermometer and Problem List (DT&PL) to assess distress and the Hospital Anxiety and Depression Scale (HADS) to assess distress, anxiety, and depression. They provided information on how their MPN affected their lives. RESULTS: Of the 117 participants, 31.2% had PV, 28.4% had ET, 28.4% had MF, and 11.9% had another type of MPN. Time with MPN varied from less than 1 year (7.5%), 1 to 3 years (19.8%), 3 to 5 years (23.6%), 5 to 10 years (19.8%), and more than 10 years (29.2%). Distress averaged 3.14 (SD, 2.83; DT&PL), with 40.4% meeting NCCN criteria for distress, and averaged 8.97 (SD, 7.44; HADS), with 38.5% meeting HADS criteria for distress. Anxiety averaged 5.54 (SD, 4.37), with 31.3% meeting HADS criteria for anxiety. Depression averaged 3.4 (SD, 3.4), with 12.5% meeting HADS criteria for depression. Distress was higher for PV (3.86), MF (3.12), and "other" MPN (4.33) than it was for ET (1.81; P=.016). Distress was more common in non-white patients (P=.015) and those with either PV or MF but not ET (DT&PL ≥4; P=.038). Patients' comments described coping strategies or symptom burden. CONCLUSIONS: Distress and anxiety are highly prevalent with BCR-ABL-negative MPNs and may correspond to disease-related symptom burden. These findings deserve further study.
Assuntos
Ansiedade/epidemiologia , Depressão/epidemiologia , Proteínas de Fusão bcr-abl/metabolismo , Policitemia Vera/psicologia , Mielofibrose Primária/psicologia , Estresse Psicológico/epidemiologia , Trombocitemia Essencial/psicologia , Adulto , Fatores Etários , Idoso , Antidepressivos/uso terapêutico , Ansiedade/tratamento farmacológico , Estudos Transversais , Depressão/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Policitemia Vera/metabolismo , Prevalência , Mielofibrose Primária/metabolismo , Fatores Sexuais , Estresse Psicológico/tratamento farmacológico , Trombocitemia Essencial/metabolismo , Fatores de TempoRESUMO
Previous studies have shown that patients with polycythemia vera (PV) have poor quality of life (QoL). Similarly, it has been shown that survival is influenced by QoL. We aimed to evaluate QoL in 88 Turkish patients with PV. This cross-sectional study included cases diagnosed with PV between January 1995 and August 2019 who attended follow-up studies in the hematology department of a tertiary hospital in Türkiye between August 2019 and July 2020. Beginning in August 2019, subjects who approved study participation applied the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) questionnaire during their routine follow-up-given that they met inclusion/exclusion criteria. Individuals with comorbidities or factors influencing QoL and those with secondary PV-related conditions were excluded. Recorded data included age, sex, history of bleeding, thrombosis, erythrocytosis, leukocytosis, thrombocytosis, obesity or splenomegaly, and cytogenetic mutation profiles such as JAK2, BCR and MPL. We also assessed whether they needed phlebotomy or erythrocyte suspensions. Data concerning comorbidities and medication use were obtained from medical records. The median age of patients was 52 (44-61) years. The majority of participants were male (67.05%). Global health status score was 75 (66.67-83.33). PV patients who had required phlebotomy demonstrated higher social functioning scores (Pâ =â .004) and lower scores for loss of appetite (Pâ =â .013) and financial difficulties (Pâ =â .020) than patients without phlebotomy. PV patients who had suffered from leukocytosis demonstrated lower physical functioning scores compared to those without leukocytosis (Pâ =â .001). Patients without JAK2 exon 14 mutations had better physical (Pâ =â .016) and cognitive functioning scores (Pâ =â .048). It was found that PV patients with splenomegaly demonstrated lower physical functioning (Pâ =â .019) and higher appetite loss scores (Pâ =â .005) than those without splenomegaly. Higher leucocyte counts were associated with decreased physical functioning and greater fatigue. In conclusion, we demonstrated deterioration of physical and emotional QoL in patients diagnosed with PV. Patients with PV require individualized, patient-specific and integrated approaches in order to minimize symptoms, improve QoL, and increase survival.
Assuntos
Policitemia Vera , Qualidade de Vida , Humanos , Policitemia Vera/psicologia , Policitemia Vera/complicações , Masculino , Feminino , Pessoa de Meia-Idade , Estudos Transversais , Adulto , Turquia/epidemiologia , Inquéritos e Questionários , Flebotomia/psicologia , Nível de SaúdeRESUMO
OBJECTIVE: To investigate the intensity of burdensome symptoms using self-assessment MPN-SAF TSS in patientswith radiation-associated and spontaneous myeloproiliferative neoplasms (MPNs). MATERIALS AND METHODS: The study included 89 patients with radiation-associated and spontaneous MPNs, the bur-densome symptoms of MPN were determined using MPN-SAF TSS. RESULTS: The average score for complaints in patients with radiation-associated MPNs was significantly higher thanin patients with spontaneous MPNs - 43.46 and 25.04 points, respectively (p = 0.003). MPN patients classified bysubtypes also showed differences regarding intensity of burdensome MPN symptoms, demonstrating significantlyhigher average score of complaints among primary myelofibrosis patients (35.60), compared to polycythemia vera(29.60) and essential thrombocythemia (18.05) patients, (p = 0.005). Our study did not reveal any influence of theJAK2 V617F mutation on MPN burdensome symptoms intensity in MPN patients. CONCLUSIONS: We demonstrated a higher intensity of the MPN burdensome symptoms determined by the optimizedself-assessment MPN-SAF TSS in patients with radiation-associated, and in primary myelofibrosis patients, indicat-ing increased severity of patient's general conditions at the stage of diagnosis verification. It is advisable to usethe optimized MPN-SAF TSS at the moment of molecular genetic testing during the diagnosis of MPN for selectionor modifying treatment strategies in order to achieve better quality of life for patients.
Assuntos
Acidente Nuclear de Chernobyl , Exposição Ambiental/efeitos adversos , Policitemia Vera/fisiopatologia , Mielofibrose Primária/fisiopatologia , Exposição à Radiação/efeitos adversos , Trombocitemia Essencial/fisiopatologia , Adulto , Idoso , Feminino , Expressão Gênica , Humanos , Janus Quinase 2/genética , Masculino , Pessoa de Meia-Idade , Mutação , Policitemia Vera/etiologia , Policitemia Vera/genética , Policitemia Vera/psicologia , Mielofibrose Primária/etiologia , Mielofibrose Primária/genética , Mielofibrose Primária/psicologia , Qualidade de Vida/psicologia , Doses de Radiação , Radiação Ionizante , Autoavaliação (Psicologia) , Índice de Gravidade de Doença , Trombocitemia Essencial/etiologia , Trombocitemia Essencial/genética , Trombocitemia Essencial/psicologia , UcrâniaAssuntos
Carbamatos/uso terapêutico , Policitemia Vera/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Carbamatos/efeitos adversos , Feminino , Humanos , Janus Quinase 2/genética , Masculino , Dose Máxima Tolerável , Pessoa de Meia-Idade , Mutação , Policitemia Vera/genética , Policitemia Vera/psicologia , Qualidade de VidaRESUMO
The quality of life (QoL) at the time of diagnosis of myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 with essential thrombocythemia (ET), 73 with polycythemia vera (PV), 22 with primary myelofibrosis (PMF) and four with MPN undifferentiated, were included in this study. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQC30) and the MPN-Symptom Assessment Form (MPN-SAF) were used to evaluate QoL. Fatigue was the most reported symptom in these patients. Patients with PV reported significantly higher mean scores for inactivity, dizziness, cough, itching, depression and lower total QoL compared to patients with ET. Patients with PV had significantly more headache and itching compared to patients with PMF. When the newly diagnosed patients with MPN were compared with a cohort of patients with MPN with mean disease duration of 7.8 years, the differences were most striking for patients with PMF, with significantly more fatigue, abdominal discomfort, concentration problems, insomnia, fever, weight loss and lower overall QoL developed over time.
Assuntos
Transtornos Mieloproliferativos/psicologia , Policitemia Vera/psicologia , Qualidade de Vida , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Inquéritos Epidemiológicos , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/diagnóstico , Policitemia Vera/diagnóstico , Inquéritos e QuestionáriosAssuntos
Envelhecimento , Neoplasias/etiologia , Estresse Psicológico/complicações , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/imunologia , Envelhecimento/psicologia , Suscetibilidade a Doenças , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Personalidade , Policitemia Vera/psicologia , Prognóstico , Isolamento Social , Estresse Psicológico/fisiopatologiaRESUMO
A patient with polycythaemia rubra vera is described, presenting primarily with symptoms attributed to depression. While in the ward she developed a stroke, confirmed on CT scan of the head. Venesection alone produced marked improvement in her neurological and psychiatric symptoms. The clinical picture corresponds most accurately to the neurological syndrome of abulia, which is an important differential diagnosis of depression with psychomotor retardation. The pathophysiology of impaired cerebral blood flow causing neuropsychiatric symptoms in polycythaemia is discussed.
Assuntos
Depressão/etiologia , Policitemia Vera/psicologia , Volição , Adulto , Sangria , Feminino , Humanos , SíndromeRESUMO
The case is described of a 65-year-old woman who initially presented with delirium caused by polycythaemia rubra vera. Following venesection she was discharged home recovered, but presented again shortly after with an episode of mania associated with relapse of her polycythaemia.
Assuntos
Transtorno Bipolar/etiologia , Delírio/etiologia , Transtornos Neurocognitivos/etiologia , Policitemia Vera/complicações , Idoso , Transtorno Bipolar/psicologia , Contagem de Células Sanguíneas , Sangria , Delírio/psicologia , Feminino , Humanos , Transtornos Neurocognitivos/psicologia , Exame Neurológico , Testes Neuropsicológicos , Policitemia Vera/psicologia , RecidivaRESUMO
A patient with polycythaemia rubra vera complicated by severe psychotic depression is described. There have been no previous reports of polycythaemia rubra vera associated with psychiatric morbidity.